Skip to main content

Table 1 Clinical characteristics of patients in our cohort (n = 82)

From: Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury

Characteristic No. of patients (%)
Mean age (standard deviation) 57 years (14)
Male sex 54 (66)
Race/ethnicity
 White 63 (77)
 Black 7 (9)
 Hispanic 9 (11)
 Other 3 (4)
Baseline risk factors
 History of smoking 35 (43)
 Alcohol consumption 35 (43)
 Type II diabetes mellitus 21 (26)
 Drug allergy 51 (62)
 Prior history of pancreatitis 7 (9)
 Pancreatic metastasis 11 (13)
Cancer type
 Melanoma 30 (37)
 Genitourinary 24 (29)
 Lung, head and neck 11 (13)
 Gastrointestinal 5 (6)
 Other solid tumors 5 (6)
 Hematologic malignancies 7 (9)
Cancer stagea
 Stage III 3 (4)
 Stage IV 72 (96)
Median number of immune checkpoint inhibitor doses (interquartile range) 4 (1-25)
Checkpoint inhibitor type
 CTLA-4 monotherapy 12 (15)
 PD-1/L1 monotherapy 53 (65)
 Combination therapyb 17 (21)
Other immune-related adverse events
 Gastrointestinal 27 (33)
 Hepatic 17 (21)
 Dermatologic 13 (16)
 Endocrine 7 (9)
 Pulmonary 5 (6)
 Other 6 (7)
  1. aCancer stage was recorded for 75 patients. For solid tumors, the TNM system of the American Joint Committee on Cancer 7th edition was used for cancer staging. No cancer stage was record for hematologic cancer
  2. bCombination of CTLA-4 and PD-1 or PD-L1 therapy